Hemcheck has received a first smaller order from Astemed, which is the company's distributor in the United Arab Emirates. The order concerns instruments and v-Test and is of minor economic value.
- It is very positive with a first order from Astemed and the United Arab Emirates. There is a very interesting potential in the regional market, and we of course hope that this is the first in a series of orders from there, says Joen Averstad, acting CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, acting CEO
Tel: +46 76 108 8191
Email: joen.averstad@hemcheck.com
About Hemcheck
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck's goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca,is the Certified Adviser to the company.